What We Do

OUR MISSION

NVP is advancing a new generation of targeted nanosphere (TNS) based products incorporating our core and highly optimized HPLN (Hybrid Polymerized Liposomal Nanoparticle) technology. These targeted nanospheres may provide a vast improvement in flexibility and choice for patients restricted by current treatment options including antibody, immunotherapy and ADC based products. Both by repositioning existing therapies such as chemotherapeutics and by optimising the delivery of emerging candidates including small molecules and nucleic acid based.

Our current main candidate focus is in oncology, initially pediatric focused, with NV103, but it is already clear that once validated the technology can be applied to broader oncology challenges, as well as areas such as surgery/devices where we have a pipeline candidate, imaging, vaccines, and other non-oncological sectors such as neurology as opportunities present. We have other candidates such as NV101, NV102 and NV201 plus rapidly progressing pilot programs in nucleic acid delivery and in trans-BBB (blood brain barrier) related therapy for brain located cancers.

Our Technology

NVP is using HPLN as a base entity to obtain an advanced, targeted nanosphere based approach able to significantly reposition and enhance existing cancer therapies.

This is because HPLN provides a unique new nanoparticle encapsulating platform designed to harness and enable vastly superior targeting to tumor and other specific cell surface antigens. Also, unlike other targeted technologies, the ‘payload’ incorporated into HPLN, enabling powerful targeted nanospheres (TNS), can be more easily user selected, including proven cytotoxics, nucleic acid based entities or small molecules, or even any mixture thereof. HPLN technology is subject to broad patent control by NVP.

HPLN and the resultant TNS candidates may serve as an important new, effective and safe drug delivery platform to initially treat both Ewing sarcoma and human adult leukemia as well as other CD99/CD19 based tumors, via our own in-house candidates and beyond via collaborative programs. Logically the technology is widely applicable to other targeting capability, malignancies and therapeutic or even diagnostic opportunities as further candidate options develop.

Why is HPLN and the TNS approach unique?

We already have excellent chemotherapeutic compounds and rich knowledge in their everyday use, plus emerging tumor-specific biologicals. However, the key issues that our approach can clearly address include:

– Improving both efficacy and capability of existing agents in existing settings

– Improving applicability of existing drugs to ‘new cancers’

– Improving management of toxicity

– Improving scheduling practicalities with treatments

– Developing innovative or enhanced methods of delivering potential new entities or treatments via TNS either in oncology or other therapeutic areas